JCRB1589 iCS-02
Cell information
Important Notice(s)Cell type：genetically-modified cells (View Pricing Information)
| JCRB No. | JCRB1589 | Cell Name | iCS-02 |
|---|---|---|---|
| Profile | Induced chondrosarcoma cells derived from human placenta, infected with recombinant retroviruses expressing the five factors (BCL6, T, c-MYC, MITF and BAF60C). | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | F | Age | |
| Identity | available | Tissue for Primary Cancer | |
| Case history | Metastasis | ||
| Tissue Metastasized | Genetics | Induced chondrosarcoma cells derived from human placenta, infected with recombinant retroviruses expressing the five factors (BCL6, T, c-MYC, MITF and BAF60C). | |
| Life Span | infinite | Crisis PDL | |
| Morphology | ES-like | Character | |
| Classify | transformed | Established by | Umezawa, A. |
| Registered by | Umezawa, A. | Regulation for Distribution | |
| Comment | Year | 2013 | |
| Medium | Poweredby10 | Methods for Passages | Subculture once a week by Physical method or enzyme-treatment method. (Cells were maintained on mouse primary embryonic fibroblast feeder cells inactivated with mitomycin C.) |
| Cell Number on Passage | Race | ||
| CO2 Conc. | 5% | Tissue Sampling | Decidua |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:22833560 | Placenta to cartilage: direct conversion of human placenta to chondrocytes with transformation by defined factors. Ishii R,Kami D,Toyoda M,Makino H,Gojo S,Ishii T,Umezawa A Mol Biol Cell. 2012 Sep;23(18):3511-21 |
LOT Information
Viability/Growth rate/Cell number are represented as actual values measured at lot presentation in JCRB, but are not guaranteed values. Additionally, the doubling time is a rough value measured during passages.| Cell No. | JCRB1589 | Cell Name | iCS-02 |
|---|---|---|---|
| LOT No. | 06092014 | Lot Specification | distribution |
| Medium | POWEREDBY10(within serum and biotics) on mitomycin C-treated MEF feeder cells (ICR) | Temperature | 37 C |
| Cell Density at Seeding | 3-5x10^4 cells/sq.cm | Methods for Passages | Cells were harvested after treatment with 0.25%trypsin(GIBCO) and 0.02% EDTA or mechanical(pipetting) :(1/10-1/20 split). |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 3.21x10^6 |
| Viability at cell freezing (%) | 92.6 | Antibiotics Used | NT |
| Passage Number | p13 | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:10,11 D13S317:11,12 D7S820:8,11 D16S539:12,13 VWA:16 TH01:6 AM:X TPOX:8,11 CSF1PO:11,12 |
| Adhesion | Yes | Exoteric Gene | NT |
| Medium for Freezing | BAMBANKER(LYMPHOTEC Inc.,CS-02-001,NIPPON Genetics Co., LTD) | CO2 Conc. | 5 % |
| Viability immediately after thawing (%) | Additional information | Mitomycin C-treated MEFs are used as feeders. |